Less Is More in Chemotherapy of Breast Cancer

TL;DR

This paper introduces a mathematical model for breast cancer treatment that compares metronomic chemotherapy with traditional methods, highlighting the benefits of combination therapies and the importance of immune interactions.

Contribution

The study develops a delay differential equation model capturing tumor-immune dynamics, demonstrating the effectiveness of metronomic chemotherapy and the significance of adjunct therapies.

Findings

Metronomic chemotherapy outperforms MTD in efficacy.

Oscillatory tumor dynamics pose challenges for complete elimination.

Synergistic effects enhance treatment outcomes.

Abstract

This study presents a mathematical model that captures the interactions among tumor cells, healthy cells, and immune cells in a tumor-bearing host, with a specific focus on breast cancer. Incorporating the concept of delay, the model consists of four differential equations to analyze these cellular dynamics. The findings demonstrate the superior efficacy of metronomic chemotherapy compared to the maximum tolerated dose (MTD) method and underscore the necessity of adjunct therapies. Oscillatory tumor cell dynamics revealed by the model highlight the challenges of achieving complete tumor elimination through chemotherapy alone. Sensitivity analysis confirms the robustness of the model, particularly under metronomic treatment protocols, aligning with experimental observations regarding metronomic-to-MTD dosage ratios. Furthermore, the results emphasize the importance of synergistic effects from combination therapies. This biologically consistent framework provides valuable insights into tumor-immune interactions and offers a foundation for optimizing therapeutic strategies in cancer treatment.